Type I IFN signature in primary Sjögren's syndrome patients

Expert Review of Clinical Immunology

Volumn 10, Issue 4, 2014, Pages 457-467

  Brkic, Zana ^a   Versnel, Marjan A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

BAFF; monocyte; plasmacytoid dendritic cell; Sj grens syndrome; Th17; type I interferon

Indexed keywords

ALPHA INTERFERON; B CELL ACTIVATING FACTOR; BETA INTERFERON; EPSILON INTERFERON; GAMMA INTERFERON; INTERFERON; KAPPA INTERFERON; LAMBDA INTERFERON; MYXOVIRUS RESISTANCE PROTEIN A; OMEGA INTERFERON; RONTALIZUMAB; SIFALIMUMAB; UNCLASSIFIED DRUG;

APOPTOSIS; AUTOIMMUNITY; DISEASE ACTIVITY; DRY EYE; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; HUMAN; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTION; PREVALENCE; PRIMARY SJOEGREN SYNDROME; PROTEIN EXPRESSION; REVIEW; SALIVARY GLAND BIOPSY; SJOEGREN SYNDROME; SYSTEMIC DISEASE; T LYMPHOCYTE ACTIVATION; TH17 CELL; TREATMENT RESPONSE; VASCULITIS; XEROSTOMIA;

BIOLOGICAL MARKERS; HUMANS; INTERFERON TYPE I; SALIVARY GLANDS; SJOGREN'S SYNDROME; TRANSCRIPTOME;

EID: 84896988229     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2014.876364     Document Type: Review

References (104)

1. Fox RI, Howell FV, Bone RC, Michelson P. Primary Sjogren syndrome: clinical and immunopathologic features. Semin Arthritis Rheum 1984;14(2):77-105
2. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjogren syndrome. Arch Intern Med 2004; 164(12):1275-84
3. Bayetto K, Logan RM. Sjogren's syndrome: a review of aetiology, pathogenesis, diagnosis and management. Aust Dent J 2010; 55(Suppl 1):39-47
4. Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 2009;11(3):229
5. Goransson LG, Haldorsen K, Brun JG, et al. The point prevalence of clinically relevant primary Sjogren's syndrome in two Norwegian counties. Scand J Rheumatol 2011;40(3):221-4
6. Birlik M, Akar S, Gurler O, et al. Prevalence of primary Sjogren's syndrome in Turkey: a population-based epidemiological study. Int J Clin Pract 2009;63(6):954-61
7. Alamanos Y, Tsifetaki N, Voulgari PV, et al. Epidemiology of primary Sjogren's syndrome in north-west Greece, 1982-2003. Rheumatology (Oxford) 2006;45(2):187-91
8. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61(6):554-8
9. Shiboski SC, Shiboski CH, Criswell L, et al. American College of Rheumatology classification criteria for Sjogren's syndrome: a data-driven, expert consensus approach in the Sjogren's International Collaborative Clinical Alliance cohort. Arthritis Care Res 2012;64(4):475-87
10. Nikolov NP, Illei GG. Pathogenesis of Sjogren's syndrome. Curr Opin Rheumatol 2009;21(5):465-70
11. Higgs BW, Liu Z, White B, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 2011;70(11): 2029-36
12. Stark GR, Kerr IM, Williams BR, et al. How cells respond to interferons. Annu Rev Biochem 1998;67:227-64
13. Li M, Liu X, Zhou Y, Su SB. Interferonlambdas: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol 2009;86(1):23-32
14. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957;147(927):258-67
15. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005;5(5):375-86
16. Krause CD, Pestka S. Evolution of the Class 2 cytokines and receptors, and discovery of new friends and relatives. Pharmacol Ther 2005;106(3):299-346
17. Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197(6):711-23
18. Fitzgerald-Bocarsly P, Dai J, Singh S. Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine Growth Factor Rev 2008;19(1):3-19
19. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005;23:275-306
20. Mavragani CP, Crow MK. Activation of the type I interferon pathway in primary Sjogren's syndrome. J Autoimmun 2010; 35(3):225-31
21. Lande R, Gilliet M. Plasmacytoid dendritic cells: key players in the initiation and regulation of immune responses. Ann N Y Acad Sci 2010;1183:89-103
22. Ronnblom L. The type I interferon system in the etiopathogenesis of autoimmune diseases. Ups J Med Sci 2011;116(4): 227-37
23. Ronnblom L, Alm GV, Eloranta ML. The type I interferon system in the development of lupus. Semin Immunol 2011;23(2): 113-21
24. Kalliolias GD, Ivashkiv LB. Overview of the biology of type I interferons. Arthritis Res Ther 2010;12(Suppl 1):S1
25. Gao S, von der Malsburg A, Dick A, et al. Structure of myxovirus resistance protein a reveals intra- and intermolecular domain interactions required for the antiviral function. Immunity 2011;35(4):514-25
26. Ronni T, Melen K, Malygin A, Julkunen I. Control of IFN-inducible MxA gene expression in human cells. J Immunol 1993; 150(5):1715-26
27. Haller O, Kochs G. Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral activity. J Interferon Cytokine Res 2011;31(1):79-87
28. Borden EC, Sen GC, Uze G, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007;6(12):975-90
29. Brassard DL, Grace MJ, Bordens RW. Interferon-alpha as an immunotherapeutic protein. J Leukoc Biol 2002;71(4):565-81
30. Karlsson-Parra A, Burman P, Hagberg H, et al. Autoantibodies to epithelial cells in patients on long-term therapy with leucocyte-derived interferon-alpha (IFN-alpha). Clin Exp Immunol 1990; 81(1):72-5
31. Ronnblom LE, Alm GV, Oberg KE. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med 1990;227(3):207-10
32. Oishi A, Miyamoto K, Kashii S, Yoshimura N. Abducens palsy and Sjogren's syndrome induced by pegylated interferon therapy. Br J Ophthalmol 2007;91(6):843-4
33. Onishi S, Nagashima T, Kimura H, et al. Systemic lupus erythematosus and Sjogren's syndrome induced in a case by interferon-alpha used for the treatment of hepatitis C. Lupus 2010;19(6):753-5
34. Malik UR, Makower DF, Wadler S. Interferon-mediated fatigue. Cancer 2001; 92(6 Suppl):1664-8
35. Baccala R, Kono DH, Theofilopoulos AN. Interferons as pathogenic effectors in autoimmunity. Immunol Rev 2005;204: 9-26
36. Kaser A, Nagata S, Tilg H. Interferon alpha augments activation-induced T cell death by upregulation of Fas (CD95/APO-1) and Fas ligand expression. Cytokine 1999;11(10): 736-43
37. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003;100(5):2610-15
38. Strandberg L, Ambrosi A, Espinosa A, et al. Interferon-alpha induces up-regulation and nuclear translocation of the Ro52 autoantigen as detected by a panel of novel Ro52-specific monoclonal antibodies. J Clin Immunol 2008;28(3):220-31
39. Bave U, Nordmark G, Lovgren T, et al. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005;52(4):1185-95
40. Hjelmervik TO, Petersen K, Jonassen I, et al. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis Rheum 2005; 52(5):1534-44
41. Gottenberg JE, Cagnard N, Lucchesi C, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc Natl Acad Sci USA 2006; 103(8):2770-5
42. Zheng L, Zhang Z, Yu C, et al. Association between IFN-alpha and primary Sjogren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;107(1):e12-18
43. Hua J, Kirou K, Lee C, Crow MK. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum 2006;54(6): 1906-16
44. Mavragani CP, Niewold TB, Moutsopoulos NM, et al. Augmented interferon-alpha pathway activation in patients with Sjogren's syndrome treated with etanercept. Arthritis Rheum 2007; 56(12):3995-4004
45. Niewold TB, Rivera TL, Buyon JP, Crow MK. Serum type I interferon activity is dependent on maternal diagnosis in anti- SSA/Ro-positive mothers of children with neonatal lupus. Arthritis Rheum 2008; 58(2):541-6
46. Wildenberg ME, van Helden-Meeuwsen CG, van de Merwe JP, et al. Systemic increase in type I interferon activity in Sjogren's syndrome: a putative role for plasmacytoid dendritic cells. Eur J Immunol 2008;38(7): 2024-33
47. Emamian ES, Leon JM, Lessard CJ, et al. Peripheral blood gene expression profiling in Sjogren's syndrome. Genes Immun 2009; 10(4):285-96
48. Brkic Z, Maria NI, van Helden-Meeuwsen CG, et al. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis 2013;72(5):728-35
49. Kirou KA, Lee C, George S, et al. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum 2004; 50(12):3958-67
50. Maria NI, Brkic Z, Waris M, et al. MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren's syndrome. Ann Rheum Dis 2013;doi:10.1136/annrheumdis-2012- 202552
51. Nandula SR, Dey P, Corbin KL, et al. Salivary gland hypofunction induced by activation of innate immunity is dependent on type I interferon signaling. J Oral Pathol Med 2013;42(1):66-72
52. Szczerba BM, Rybakowska PD, Dey P, et al. Type I interferon receptor deficiency prevents murine Sjogren's syndrome. J Dent Res 2013;92(5):444-9
53. Shen L, Suresh L, Malyavantham K, et al. Different stages of primary Sjogren's syndrome involving lymphotoxin and type 1 IFN. J Immunol 2013;191(2): 608-13
54. Ramos-Casals M, Brito-Zeron P, Yague J, et al. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome. Rheumatology (Oxford) 2005; 44(1):89-94
55. Theander E, Henriksson G, Ljungberg O, et al. Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006;65(6): 796-803
56. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum 2002; 46(3):741-7
57. Theander E, Vasaitis L, Baecklund E, et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndrome. Ann Rheum Dis 2011;70(8):1363-8
58. Mariette X, Roux S, Zhang J, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003;62(2): 168-71
59. Lavie F, Miceli-Richard C, Quillard J, et al. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjogren's syndrome. J Pathol 2004;202(4):496-502
60. Groom J, Kalled SL, Cutler AH, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002; 109(1):59-68
61. Ittah M, Miceli-Richard C, Eric Gottenberg J, et al. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren's syndrome. Arthritis Res Ther 2006;8(2):R51
62. Panchanathan R, Choubey D. Murine BAFF expression is up-regulated by estrogen and interferons: implications for sex bias in the development of autoimmunity. Mol Immunol 2013;53(1-2):15-23
63. Kiefer K, Oropallo MA, Cancro MP, Marshak-Rothstein A. Role of type I interferons in the activation of autoreactive B cells. Immunol Cell Biol 2012;90(5): 498-504
64. Seo YJ, Hahm B. Type I interferon modulates the battle of host immune system against viruses. Adv Appl Microbiol 2010;73:83-101
65. Ambrosi A, Espinosa A, Wahren-Herlenius M. IL-17: a new actor in IFN-driven systemic autoimmune diseases. Eur J Immunol 2012;42(9):2274-84
66. Yu CF, Peng WM, Oldenburg J, et al. Human plasmacytoid dendritic cells support Th17 cell effector function in response to TLR7 ligation. J Immunol 2010;184(3): 1159-67
67. Matikainen S, Sareneva T, Ronni T, et al. Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. Blood 1999;93(6):1980-91
68. Yasuda K, Richez C, Maciaszek JW, et al. Murine dendritic cell type I IFN production induced by human IgG-RNA immune complexes is IFN regulatory factor (IRF) 5 and IRF7 dependent and is required for IL-6 production. J Immunol 2007;178(11): 6876-85
69. Santini SM, Lapenta C, Donati S, et al. Interferon-alpha-conditioned human monocytes combine a Th1-orienting attitude with the induction of autologous Th17 responses: role of IL-23 and IL-12. PLoS ONE 2011;6(2):e17364
70. Fransen JH, van der Vlag J, Ruben J, et al. The role of dendritic cells in the pathogenesis of systemic lupus erythematosus. Arthritis Res Ther 2010; 12(2):207
71. Munoz LE, van Bavel C, Franz S, et al. Apoptosis in the pathogenesis of systemic lupus erythematosus. Lupus 2008;17(5): 371-5
72. Kong L, Ogawa N, Nakabayashi T, et al. Fas and Fas ligand expression in the salivary glands of patients with primary Sjogren's syndrome. Arthritis Rheum 1997;40(1): 87-97
73. Polihronis M, Tapinos NI, Theocharis SE, et al. Modes of epithelial cell death and repair in Sjogren's syndrome (SS). Clin Exp Immunol 1998;114(3):485-90
74. Matsumura R, Umemiya K, Goto T, et al. Interferon gamma and tumor necrosis factor alpha induce Fas expression and anti-Fas mediated apoptosis in a salivary ductal cell line. Clin Exp Rheumatol 2000;18(3): 311-18
75. Abu-Helu RF, Dimitriou ID, Kapsogeorgou EK, et al. Induction of salivary gland epithelial cell injury in Sjogren's syndrome: in vitro assessment of T cell-derived cytokines and Fas protein expression. J Autoimmun 2001;17(2): 141-53
76. Tsubota K, Fujita H, Tsuzaka K, Takeuchi T. Quantitative analysis of lacrimal gland function, apoptotic figures, Fas and Fas ligand expression of lacrimal glands in dry eye patients. Exp Eye Res 2003;76(2):233-40
77. Ishimaru N, Arakaki R, Watanabe M, et al. Development of autoimmune exocrinopathy resembling Sjogren's syndrome in estrogen-deficient mice of healthy background. Am J Pathol 2003;163(4): 1481-90
78. Carlsten H, Nilsson N, Jonsson R, et al. Estrogen accelerates immune complex glomerulonephritis but ameliorates T cell-mediated vasculitis and sialadenitis in autoimmune MRL lpr/lpr mice. Cell Immunol 1992;144(1):190-202
79. Dieker JW, Fransen JH, van Bavel CC, et al. Apoptosis-induced acetylation of histones is pathogenic in systemic lupus erythematosus. Arthritis Rheum 2007;56(6): 1921-33
80. Urbonaviciute V, Furnrohr BG, Meister S, et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med 2008;205(13):3007-18
81. Fransen JH, Hilbrands LB, Ruben J, et al. Mouse dendritic cells matured by ingestion of apoptotic blebs induce T cells to produce interleukin-17. Arthritis Rheum 2009;60(8): 2304-13
82. Fransen JH, Hilbrands LB, Jacobs CW, et al. Both early and late apoptotic blebs are taken up by DC and induce IL-6 production. Autoimmunity 2009; 42(4):325-7
83. Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med 2013; 5(178):178ra140
84. Fuchs TA, Abed U, Goosmann C, et al. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol 2007;176(2):231-41
85. Bouts YM, Wolthuis DF, Dirkx MF, et al. Apoptosis and NET formation in the pathogenesis of SLE. Autoimmunity 2012; 45(8):597-601
86. Garcia-Romo GS, Caielli S, Vega B, et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 2011; 3(73):73ra20
87. Martinelli S, Urosevic M, Daryadel A, et al. Induction of genes mediating interferon-dependent extracellular trap formation during neutrophil differentiation. J Biol Chem 2004;279(42):44123-32
88. Hakkim A, Furnrohr BG, Amann K, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci USA 2010; 107(21):9813-18
89. Leffler J, Martin M, Gullstrand B, et al. Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J Immunol 2012;188(7):3522-31
90. Miceli-Richard C, Comets E, Loiseau P, et al. Association of an IRF5 gene functional polymorphism with Sjogren's syndrome. Arthritis Rheum 2007;56(12): 3989-94
91. Nordmark G, Kristjansdottir G, Theander E, et al. Additive effects of the major risk alleles of IRF5 and STAT4 in primary Sjogren's syndrome. Genes Immun 2009;10(1):68-76
92. Merrill JT, Wallace DJ, Petri M, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis 2011;70(11):1905-13
93. Merrill J, Chindalore V, Box J, et al. Results of a randomized placebo-controlled, phase 2a study of sifalimumab, an anti-interferon-alpha monoclonal antibody, administered subcutaneously in subjects with systemic lupus erythematosus [abstract]. Presented at: EULAR; 2011. London, UK [THU0411]
94. Petri M, Wallace DJ, Spindler A, et al. Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum 2013;65(4):1011-21
95. McBride JM, Jiang J, Abbas AR, et al. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebocontrolled, double-blind, dose-escalation study. Arthritis Rheum 2012;64(11): 3666-76
96. Mathian A, Amoura Z, Adam E, et al. Active immunisation of human interferon alpha transgenic mice with a human interferon alpha Kinoid induces antibodies that neutralise interferon alpha in sera from patients with systemic lupus erythematosus. Ann Rheum Dis 2011;70(6): 1138-43
97. Lauwerys BR, Hachulla E, Spertini F, et al. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon alpha-kinoid. Arthritis Rheum 2013;65(2): 447-56
98. Blomberg S, Eloranta ML, Magnusson M, et al. Expression of the markers BDCA-2 and BDCA-4 and production of interferon-alpha by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Rheum 2003;48(9):2524-32
99. Dzionek A, Sohma Y, Nagafune J, et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J Exp Med 2001;194(12):1823-34
100. Guiducci C, Tripodo C, Gong M, et al. Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9. J Exp Med 2010; 207(13):2931-42
101. Sun X, Wiedeman A, Agrawal N, et al. Increased ribonuclease expression reduces inflammation and prolongs survival in TLR7 transgenic mice. J Immunol 2013; 190(6):2536-43
102. Sacre K, Criswell LA, McCune JM. Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res Ther 2012;14(3):R155
103. Kuznik A, Bencina M, Svajger U, et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 2011;186(8): 4794-804
104. Vitali C, Bootsma H, Bowman SJ, et al. Classification criteria for Sjogren's syndrome: we actually need to definitively resolve the long debate on the issue. Ann Rheum Dis 2013;72(4):476-8